This report describes three patients with chronic myelogenous leukemia who developed gastric antral vascular ectasia (GAVE) during treatment with imatinib mesylate (IM). Cessation and/or switching from IM to nilotinib resulted in the alleviation of gastrointestinal (GI) bleeding and ectatic lesions. Furthermore, GI bleeding recurred after the re-administration of IM in one patient. Thus, we consider that the occurrence of GAVE in our patients was induced by IM. Although the precise mechanism of IM-GAVE is not understood, all patients took at least 400 mg/day of IM at the onset of GAVE. Thus, higher doses of IM (! 400 mg/day) may be a risk factor for IM-GAVE.
Introduction
Imatinib mesylate (IM) is a clinically available selective inhibitor of intracellular ABL kinase, chimeric BCR-ABL fusion oncoprotein of chronic myelogenous leukemia (CML), transmembrane receptor KIT, and platelet-derived growth factor receptors. Since the introduction of IM for the treatment of CML, impressive clinical responses have been observed in the majority of patients in the chronic phase (CP). On the other hand, certain IM-related gastrointestinal (GI) side effects are common, such as diarrhea, nausea and vomiting. GI bleeding is a well-known complication of IM therapy in patients with gastrointestinal stromal tumors (GIST). It is estimated to occur in 1.4-5% of all IM-treated GIST patients due to IM-induced tumor necrosis (1) . Thus, in CML patients, the etiology of the GI bleeding is quite different from that in GIST patients. The present report describes three cases of patients with CML who developed gastric antral vascular ectasia (GAVE) during treatment with IM. In all cases, IM was considered to be the cause of GAVE.
Case Reports

Case 1
A 73-year-old woman was diagnosed with CML-CP, and IM treatment (400 mg, daily) was started in January 2010. The patient achieved a complete molecular response (CMR) at 6 months after IM therapy. However, she developed irondeficiency anemia in May 2010 that was refractory to oral iron supplementation. In March 2013, after the detection of occult blood in a stool sample, the patient underwent gastrointestinal endoscopy and colon fiberscopy.
No abnormalities were revealed on a physical examination and, with the exception of anemia and the mild elevation of lactate dehydrogenease, the laboratory tests were unremarkable (Table) .
Gastrointestinal endoscopy showed oozing blood with vascular ectasia in the gastric corpus and antrum (Figure) . Furthermore, colon fiberscopy showed capillary dilatation in the rectal mucosa without bleeding. The patient underwent gastrointestinal mucosal ablation by argon plasma coagula- tion (APC) and endoscopic mucosal resection in the rectum. IM was replaced with nilotinib (800 mg, daily). Currently, the patient remains in a state of CMR with nilotinib, and the iron deficiency anemia has been completely resolved.
Case 2
A 57-year-old man was diagnosed with CML-CP in November 1993. Interferon-α treatment was started but later discontinued due to severe side effects. IM was started in December 2001 and was continued at a dose of 100-200 mg/day. However, the patient developed CML blastic crisis (CML-BC) in December 2006. Since the patient refused hematopoietic stem cell transplantation and chemotherapies other than IM, the dose of IM was increased to up to 800 mg/day, which achieved the control of his disease. The patient noted tarry stool and vomited a large amount of blood in the beginning of March, 2007. A physical examination revealed pallor of the conjunctiva and skin, while the laboratory data showed severe anemia (hemoglobin, 2.8 g/dL), leukocytopenia, thrombocytopenia, renal dysfunction due to chronic kidney disease, and the mild elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and LDH (Table) . Emergent upper GI endoscopy was performed on the day after the onset of hematemesis, showed vascular ectasia in the gastric corpus and antrum with bleeding. Drug-induced GAVE was suspected and the IM treatment was stopped. The patient's condition stabilized after a massive transfusion of red blood cells and platelets. Treatment with proton pump inhibiter (omeprazole) was started. Although no obvious GI bleeding occurred after the cessation of IM, GI bleeding recurred about 4 weeks after IM treatment was restarted (800 mg, daily).
Case 3
A 58-year-old woman with CML lymphoid crisis received IM (600 mg/day) as part of a remission induction therapy in December 2009. The patient achieved complete remission (CR) and received consolidation therapy in February 2010, which consisted of high-dose methotrexate, high-dose cytarabine, methylprednisolone, and subsequent IM (600 mg/ day). However, 9 days after starting IM treatment, the patient developed tarry stool. At that time, patient had mild pitting edema in the bilateral lower extremities. Laboratory tests showed severe cytopenias associated with the consolidation therapy, and the mild elevation of AST, ALT, and LDH (Table) . Upper GI endoscopy showed gastric telangiectasia with oozing blood in the gastric corpus and antrum. IM was stopped due to suspected IM-induced GAVE and switched to nilotinib. The GI bleeding resolved 1 week after the cessation of IM treatment. The complete resolution of GAVE was confirmed by an endoscopic reevaluation, which was performed 6 weeks after the onset of GI bleeding (3 weeks after starting nilotinib treatment). The patient received a peripheral blood stem cell transplantation from a human leukocyte antigen-matched sibling in April 2010 and has maintained a CR since that time.
Discussion
Our three patients developed GI bleeding with ectatic vessel lesions in the stomach during IM therapy. Between January 2005 and December 2014, a total of 164 patients received IM therapy, and 6 patients were diagnosed with GAVE in the hematology division of our hospital. GAVE is a rare disorder that is endoscopically characterized by red patches or spots in either a diffuse or linear array in the antrum. All of our patients showed diffuse telangiectatic lesions in both the corpus and antrum. In GAVE, ectatic vessels are typically limited to the antrum. However, in one report, patients with GAVE occasionally showed extra-antral lesions (2) . GAVE is generally associated with underlying chronic disease. Liver cirrhosis is found in 30% of patients with GAVE, whereas autoimmune diseases are most common in non-cirrhotic patients with GAVE (3). However, none of our three patients showed any obvious symptoms/ findings of liver cirrhosis or autoimmune disease. Among patients with hematologic disorders, GAVE or GAVE-like disorder can be caused by cytotoxic drugs, especially oral busulfan, in patients undergoing hematopoietic stem cell transplantation (HSCT), or by acute myeloid leukemia itself (4-6). IM has also been reported to be a cause of GAVE (7, 8) . These results indicate that certain types of drugs can induce GAVE. In our cases, CML was unlikely to have caused GAVE, because the patient in Case 1 developed GAVE despite maintaining a CMR. Furthermore, in all three cases, the GI bleeding subsided after the cessation of IM, whereas in Case 2, GI bleeding recurred after the resumption of IM treatment. Thus, we hypothesized that IM was the cause of our patients' GAVE.
The pathogenesis of GAVE is poorly understood. Some authors have linked GAVE with the elevated local concentration of vasoactive substances, such as gastrin, prostaglandin E2, serotonin, or vasoactive intestinal peptide (VIP) (9, 10). Mechanical stress in the antrum has also been suggested as a cause of GAVE, based on the results of an antral motility study (11). In the case of HSCT-GAVE, direct mucosal damage and/or the sinusoidal obstructionassociated elevation of portal vein pressure by busulfan have been reported to be possible causes of GAVE. IM has been reported to inhibit the pacemaker potential of Cajal cells in a mouse model (12). Thus, a change in stomach motility via altered Cajal cell function might be an etiology of IM-GAVE. All of our patients received at least 400 mg/day of IM at the onset of GAVE. In addition, GAVE occurred at a relatively early phase of IM therapy. Of interest, in Case 2, GAVE did not occur when the patient received a low dose of IM, despite a long treatment period. Thus, a higher dose (! 400 mg/day) of IM may be a risk factor for the development of IM-GAVE (7). With respect to the patients' treatment, IM was stopped in Cases 2 and 3, and one patient (Case 1) underwent APC. The patients' GI bleeding subsided after the cessation IM. In Cases 1 and 3, IM was finally switched to nilotinib and the patients' subsequent clinical courses were quite favorable, without further GI bleeding. Thus, the cessation of IM and a switch to another tyrosine kinase inhibitor seemed to be a suitable strategy for the treatment of GAVE in patients with CML. However, careful attention should be paid to the possibility that GAVE could also be induced by other tyrosine kinase inhibitors.
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